Roche Causes Stir With Tecentriq/Avastin/Chemo Lung Cancer Win

 
• By Kevin Grogan

There are no actual data yet but the news that the closely-watched IMpower 150 study met a goal of progression-free survival and showed 'encouraging' signs on the overall survival endpoint has made IO rivals sit up, especially Merck & Co.

Thumbs up
Roche's closely watched lung cancer trial has succeeded • Source: Shutterstock

More from Immuno-oncology

More from Anticancer